{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:11:56Z","timestamp":1782259916484,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["19H03591"],"award-info":[{"award-number":["19H03591"]}]},{"name":"Yanai Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-04715-9","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T09:02:53Z","timestamp":1749200573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mathematical mechanistic model representing the cancer immunity cycle under radiation effects"],"prefix":"10.1038","volume":"15","author":[{"given":"Taisuke","family":"Takayanagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futaro","family":"Ebina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kanehira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Kobashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Shirato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Chamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"4","key":"4715_CR1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djs629","volume":"105","author":"SC Formenti","year":"2013","unstructured":"Formenti, S. C. & Demaria, S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl. Cancer Inst. 105(4), 256\u2013265 (2013).","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"4715_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","volume":"11","author":"Y Liu","year":"2018","unstructured":"Liu, Y. et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J. Hematol. Oncol. 11(1), 104 (2018).","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"4715_CR3","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.3390\/cancers12102762","volume":"12","author":"X Zhao","year":"2020","unstructured":"Zhao, X. & Shao, C. Radiotherapy-mediated immunomodulation and anti-tumor abscopal effect combining immune checkpoint Blockade. Cancers 12(10), 2762 (2020).","journal-title":"Cancers"},{"issue":"20","key":"4715_CR4","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl. J. Med. 377(20), 1919\u20131929 (2017).","journal-title":"N Engl. J. Med."},{"issue":"4","key":"4715_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","volume":"20","author":"M McLaughlin","year":"2020","unstructured":"McLaughlin, M. et al. Inflammatory microenvironment remodeling by tumour cells after radiotherapy. Nat. Rev. Cancer. 20(4), 203\u2013217 (2020).","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"4715_CR6","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/stem.3391","volume":"39","author":"M R\u00fcckert","year":"2021","unstructured":"R\u00fcckert, M. et al. Radiotherapy and the immune system: more than just immune suppression. Stem Cells. 39(9), 1155\u20131165 (2021).","journal-title":"Stem Cells"},{"issue":"20","key":"4715_CR7","doi-asserted-by":"publisher","first-page":"11061","DOI":"10.3390\/ijms222011061","volume":"22","author":"JR Janopaul-Naylor","year":"2021","unstructured":"Janopaul-Naylor, J. R. et al. The abscopal effect: A review of pre-clinical and clinical advances. Int. J. Mol. Sci. 22(20), 11061 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"4715_CR8","doi-asserted-by":"publisher","first-page":"101366","DOI":"10.1016\/j.tranon.2022.101366","volume":"19","author":"D Zhai","year":"2022","unstructured":"Zhai, D. et al. Radiotherapy: brightness and darkness in the era of immunotherapy. Transl Oncol. 19, 101366 (2022).","journal-title":"Transl Oncol."},{"issue":"1","key":"4715_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal. Transduct. Target. Ther. 7(1), 258 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"8","key":"4715_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","volume":"20","author":"L Galluzzi","year":"2023","unstructured":"Galluzzi, L., Aryankalayil, M. J., Coleman, C. N. & Formenti, S. C. Emerging evidence for adapting radiotherapy to immunotherapy. Nat. Rev. Clin. Oncol. 20(8), 543\u2013557 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"4715_CR11","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.ijrobp.2022.09.003","volume":"114","author":"LK Mell","year":"2022","unstructured":"Mell, L. K. et al. Radiotherapy with durvalumab vs. cetuximab in patients with locoregionally advanced head and neck cancer and a contraindication to cisplatin: phase II results of NRG-HN004. Int. J. Radiat. Oncol. Biol. Phys. 114(5), 1058 (2022).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"4715_CR12","doi-asserted-by":"publisher","first-page":"799957","DOI":"10.3389\/fonc.2021.799957","volume":"11","author":"L Wen","year":"2021","unstructured":"Wen, L. et al. The research progress of PD-1\/PD-L1 inhibitors enhancing radiotherapy efficacy. Front. Oncol. 11, 799957 (2021).","journal-title":"Front. Oncol."},{"issue":"4","key":"4715_CR13","doi-asserted-by":"publisher","first-page":"e002038","DOI":"10.1136\/jitc-2020-002038","volume":"9","author":"S Demaria","year":"2021","unstructured":"Demaria, S. et al. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J. Immunother Cancer. 9(4), e002038 (2021).","journal-title":"J. Immunother Cancer"},{"issue":"1","key":"4715_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1), 1\u201310 (2013).","journal-title":"Immunity"},{"key":"4715_CR15","doi-asserted-by":"publisher","first-page":"622509","DOI":"10.3389\/fimmu.2020.622509","volume":"11","author":"W Jiang","year":"2021","unstructured":"Jiang, W. et al. Exhausted CD8\u2009+\u2009T cells in the tumor immune microenvironment: new pathways to therapy. Front. Immunol. 11, 622509 (2021).","journal-title":"Front. Immunol."},{"issue":"8","key":"4715_CR16","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25(8), 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"issue":"5","key":"4715_CR17","doi-asserted-by":"publisher","first-page":"E761","DOI":"10.1073\/pnas.1620433114","volume":"114","author":"K Chamoto","year":"2017","unstructured":"Chamoto, K. et al. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc. Natl. Acad. Sci. U S A. 114(5), E761\u2013E770 (2017).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"11","key":"4715_CR18","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-18-0095","volume":"6","author":"PS Chowdhury","year":"2018","unstructured":"Chowdhury, P. S., Chamoto, K., Kumar, A. & Honjo, T. PPAR-Induced fatty acid oxidation in T cells increases the number of tumor-reactive CD8+ T cells and facilitates Anti-PD-1 therapy. Cancer Immunol. Res. 6(11), 1375\u20131387 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"4715_CR19","doi-asserted-by":"crossref","unstructured":"Takeshima, T. et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. (2010).","DOI":"10.1158\/0008-5472.CAN-09-2982"},{"issue":"2","key":"4715_CR20","doi-asserted-by":"publisher","first-page":"e000867","DOI":"10.1136\/jitc-2020-000867","volume":"8","author":"ZS Buchwald","year":"2020","unstructured":"Buchwald, Z. S. et al. Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy. J. Immunother Cancer. 8(2), e000867 (2020).","journal-title":"J. Immunother Cancer"},{"issue":"20","key":"4715_CR21","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","volume":"24","author":"AE Marciscano","year":"2018","unstructured":"Marciscano, A. E. et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin. Cancer Res. 24(20), 5058\u20135071 (2018).","journal-title":"Clin. Cancer Res."},{"key":"4715_CR22","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618 (2017).","journal-title":"Nat. Commun."},{"key":"4715_CR23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1200\/PO.19.00381","volume":"4","author":"J Ciccolini","year":"2020","unstructured":"Ciccolini, J. et al. Mechanistic learning for combinatorial strategies with Immuno-oncology drugs: can model-informed designs help investigators?? JCO Precis Oncol. 4, 486\u2013491 (2020).","journal-title":"JCO Precis Oncol."},{"issue":"4","key":"4715_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/imammb\/dqp005","volume":"26","author":"O Sotolongo-Grau","year":"2009","unstructured":"Sotolongo-Grau, O. et al. Immune system-tumour efficiency ratio as a new oncological index for radiotherapy treatment optimization. Math. Med. Biol. 26(4), 297\u2013307 (2009).","journal-title":"Math. Med. Biol."},{"issue":"1","key":"4715_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-018-0327-9","volume":"6","author":"Y Kosinsky","year":"2018","unstructured":"Kosinsky, Y. et al. Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model. J. Immunother Cancer. 6(1), 17 (2018).","journal-title":"J. Immunother Cancer"},{"issue":"4","key":"4715_CR26","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.ijrobp.2022.03.030","volume":"113","author":"T Friedrich","year":"2022","unstructured":"Friedrich, T., Scholz, M. & Durante, M. A predictive biophysical model of the combined action of radiation therapy and immunotherapy of cancer. Int. J. Radiat. Oncol. Biol. Phys. 113(4), 872\u2013884 (2022).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"4715_CR27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1158\/0008-5472.CAN-15-1423","volume":"76","author":"JT Poleszczuk","year":"2016","unstructured":"Poleszczuk, J. T. et al. Abscopal benefits of localized radiotherapy depend on activated T-cell trafficking and distribution between metastatic lesions. Cancer Res. 76(5), 1009\u20131018 (2016).","journal-title":"Cancer Res."},{"issue":"11","key":"4715_CR28","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.3390\/ijms19113377","volume":"19","author":"J Poleszczuk","year":"2018","unstructured":"Poleszczuk, J. & Enderling, H. The optimal radiation dose to induce robust systemic Anti-Tumor immunity. Int. J. Mol. Sci. 19(11), 3377 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"4715_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.radonc.2020.07.025","volume":"151","author":"W Sung","year":"2020","unstructured":"Sung, W. et al. A tumor-immune interaction model for hepatocellular carcinoma based on measured lymphocyte counts in patients undergoing radiotherapy. Radiother Oncol. 151, 73\u201381 (2020).","journal-title":"Radiother Oncol."},{"issue":"4","key":"4715_CR30","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.ijrobp.2021.11.008","volume":"112","author":"W Sung","year":"2022","unstructured":"Sung, W. et al. Mathematical modeling to simulate the effect of adding radiation therapy to immunotherapy and application to hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 112(4), 1055\u20131062 (2022).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"4715_CR31","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","volume":"3","author":"SS Park","year":"2015","unstructured":"Park, S. S. et al. PD-1 restrains radiotherapy-Induced abscopal effect. Cancer Immunol. Res. 3(6), 610\u2013619 (2015).","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"4715_CR32","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2021.03.047","volume":"110","author":"C Moore","year":"2021","unstructured":"Moore, C. et al. Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) in preclinical models enhances single-agent immune checkpoint blockade. Int. J. Radiat. Oncol. Biol. Phys. 110(5), 1306\u20131316 (2021).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"4715_CR33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","volume":"13","author":"CM van Leeuwen","year":"2018","unstructured":"van Leeuwen, C. M. et al. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat. Oncol. 13(1), 96 (2018).","journal-title":"Radiat. Oncol."},{"issue":"2","key":"4715_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S1074-7613(01)00094-2","volume":"14","author":"D Schrama","year":"2001","unstructured":"Schrama, D. et al. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 14(2), 111\u2013121 (2001).","journal-title":"Immunity"},{"issue":"24","key":"4715_CR35","first-page":"8794","volume":"61","author":"CJ Kirk","year":"2001","unstructured":"Kirk, C. J. et al. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res. 61(24), 8794\u20138802 (2001).","journal-title":"Cancer Res."},{"key":"4715_CR36","doi-asserted-by":"crossref","unstructured":"Scharping, N. E. et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat. Immunol 22(2), 205\u2013215 .","DOI":"10.1038\/s41590-020-00834-9"},{"key":"4715_CR37","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2307\/3576626","volume":"8","author":"JT Lyman","year":"1985","unstructured":"Lyman, J. T. Complication probability as assessed from dose-volume histograms. Radiat. Res. 8, S13\u2013S19 (1985).","journal-title":"Radiat. Res."},{"key":"4715_CR38","doi-asserted-by":"publisher","first-page":"612072","DOI":"10.3389\/fimmu.2020.612072","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang, Y. Advances in hypofractionated irradiation-induced immunosuppression of tumor microenvironment. Front. Immunol. 11, 612072 (2021).","journal-title":"Front. Immunol."},{"key":"4715_CR39","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3389\/fonc.2020.00997","volume":"10","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Low lymphocyte count is associated with radiotherapy parameters and affects the outcomes of esophageal squamous cell carcinoma patients. Front. Oncol. 10, 997 (2020).","journal-title":"Front. Oncol."},{"issue":"4","key":"4715_CR40","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","volume":"11","author":"M Aldea","year":"2021","unstructured":"Aldea, M. et al. Overcoming resistance to tumor-targeted and immune-targeted therapies. Cancer Discov. 11(4), 874\u2013899 (2021).","journal-title":"Cancer Discov"},{"key":"4715_CR41","doi-asserted-by":"publisher","first-page":"723609","DOI":"10.3389\/fimmu.2021.723609","volume":"12","author":"L Meng","year":"2021","unstructured":"Meng, L. et al. The combination of radiotherapy with immunotherapy and potential predictive biomarkers for treatment of non-small cell lung cancer patients. Front. Immunol. 12, 723609 (2021).","journal-title":"Front. Immunol."},{"issue":"12","key":"4715_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin, P. et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp. Mol. Med. 50(12), 1\u201311 (2018).","journal-title":"Exp. Mol. Med."},{"key":"4715_CR43","doi-asserted-by":"publisher","first-page":"112470","DOI":"10.1016\/j.biopha.2021.112470","volume":"147","author":"N Li","year":"2022","unstructured":"Li, N. et al. Biomarkers related to immune checkpoint inhibitors therapy. Biomed. Pharmacother. 147, 112470 (2022).","journal-title":"Biomed. Pharmacother"},{"issue":"3","key":"4715_CR44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.15537\/smj.2021.42.3.20210660","volume":"42","author":"AF Alfouzan","year":"2021","unstructured":"Alfouzan, A. F. Radiation therapy in head and neck cancer. Saudi Med. J. 42(3), 247\u2013254 (2021).","journal-title":"Saudi Med. J."},{"issue":"4","key":"4715_CR45","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.21037\/tlcr-20-627","volume":"10","author":"S Mercieca","year":"2021","unstructured":"Mercieca, S., Belderbos, J. S. A. & van Herk, M. Challenges in the target volume definition of lung cancer radiotherapy. Transl Lung Cancer Res. 10(4), 1983\u20131998 (2021).","journal-title":"Transl Lung Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04715-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04715-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04715-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T11:02:06Z","timestamp":1749207726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04715-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4715"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-04715-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19940"}}